Skip to main content

Table 1 Summary of patient and treatment parameters

From: Stereotactic radiosurgery for treating meningiomas eligible for complete resection

No. of patients 188
No. of meningiomas 218
Sex (f:m) (No., %) 148 (78.7%): 40 (21.3%)
Age at day of treatment (median, mean, SD, range in years) 60.0, 60.3, 12.6, 22.7–86.6
Laterality (No. %) Left 94 (43.1%); right 85 (39.0%);
  Medial 39 (17.9%)
Localization (No. %) Frontal 53 (24.3%)
Posterior fossa 47 (21.6%)
Parietal 19 (8.7%)
Clivus/sellar/foramen magnum 19 (8.7%)
Olfactrory grove 18 (8.3%)
Lateral sphenoid 14 (6.4%)
Medial sphenoid 13 (6.0%)
Temporal 13 (6.0%)
Occipital 12 (5.5%)
Tentorial 9 (4.1%)
Other 1 (0.5%)
Adverse Events
Early  adverse events (n patients; %) Headache 9 (4.7%)
Dizziness/vertigo 4 (2.1%)
Seizure(s) 3 (1.6%)
Cranial nerve deficits 2 (1.1%)
Facial pain 1 (0.5%)
Visual field deficit 1 (0.5%)
Other 1 (0.5%)
All adverse events rated CTCAE Grade 1 or 2
Late  adverse events (n patients; %) Headache 8 (4.2%)
Dizziness/vertigo 8 (4.2%)
Cranial nerve deficits 7 (3.7%)
Seizure(s) 2 (1.1%)*
Visual field deficit 1 (0.5%)
Other 1 (0.5%)
All adverse events rated CTCAE grade 1 or 2 except *one case with intractable sensible seizures (CTCAE grade 3)
Irradiation technique (n; %) Modified LINAC 91 (41.7%)
Cyberknife 127 (58.3%)
Single fraction SRS 206 (94.5%)
Multi fraction SRS* 12 (5.5%)
Irradiation parameters (median; SD; range) Target volume (ml) 2.9 ± 3.9; 0.1–22.0
Prescribed dose(Gy) 13.0 ± 3.1; 10.0–25.0*
Isodose level (%) 80.0 ± 11.1; 33.0–96.0
Coverage (%) 99.3 ± 3.1; 69.9–100.0
*(Multi-fraction SRS 5 × 5 Gy)